Immune system and melanoma biology: a balance between immunosurveillance and immune escape

Anna Passarelli; Francesco Mannavola; Luigia Stefania Stucci; Marco Tucci; Francesco Silvestris

doi:10.18632/oncotarget.22190

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Immune system and melanoma biology: a balance between immunosurveillance and immune escape

Anna Passarelli _, Francesco Mannavola, Luigia Stefania Stucci, Marco Tucci and Francesco Silvestris

PDF | HTML | How to cite

Oncotarget. 2017; 8:106132-106142. https://doi.org/10.18632/oncotarget.22190

Metrics: PDF 3681 views | HTML 6483 views | ?

Abstract

Anna Passarelli1, Francesco Mannavola1, Luigia Stefania Stucci1, Marco Tucci1 and Francesco Silvestris1

1Department of Biomedical Sciences and Human Oncology, University of Bari ‘Aldo Moro’, Bari, Italy

Correspondence to:

Anna Passarelli, email: [email protected]

Keywords: melanoma; immune system; immunogenicity; immunoediting; immune escape

Received: May 26, 2017 Accepted: September 21, 2017 Published: October 31, 2017

ABSTRACT

Melanoma is one of the most immunogenic tumors and its relationship with host immune system is currently under investigation. Many immunomodulatory mechanisms, favoring melanomagenesis and progression, have been described to interfere with the disablement of melanoma recognition and attack by immune cells resulting in immune resistance and immunosuppression. This knowledge produced therapeutic advantages, such as immunotherapy, aiming to overcome the immune evasion.

Here, we review the current advances in cancer immunoediting and focus on melanoma immunology, which involves a dynamic interplay between melanoma and immune system, as well as on effects of “targeted therapies” on tumor microenvironment for combination strategies.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22190

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Immune system and melanoma biology: a balance between immunosurveillance and immune escape

Abstract